US 12,435,062 B2
Amide compounds and uses thereof
Wei-Guo Su, Shanghai (CN); Weihan Zhang, Shanghai (CN); and Haibin Yang, Shanghai (CN)
Assigned to HUTCHISON MEDIPHARMA LIMITED, Shanghai (CN)
Appl. No. 17/995,172
Filed by HUTCHISON MEDIPHARMA LIMITED, Shanghai (CN)
PCT Filed Mar. 29, 2021, PCT No. PCT/CN2021/083664
§ 371(c)(1), (2) Date Sep. 30, 2022,
PCT Pub. No. WO2021/197276, PCT Pub. Date Oct. 7, 2021.
Claims priority of application No. 202010235798.3 (CN), filed on Mar. 30, 2020.
Prior Publication US 2023/0174513 A1, Jun. 8, 2023
Int. Cl. C07D 401/14 (2006.01); A61K 45/06 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01)
CPC C07D 401/14 (2013.01) [A61K 45/06 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07B 2200/05 (2013.01)] 20 Claims
 
1. A compound of formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, and/or a deuterate, a solvate, a racemic mixture, an enantiomer, a diastereomer and a tautomer thereof, wherein
X is N;
Z1 and Z2 are both CH;
Y1 is CR7; Y2 is N; Y3 is CR9;
L is O;
W is absent;
R1 is 5-12 membered heteroaryl, which is optionally substituted with one or more groups chosen from: halogen, C1-6 alkyl, C1-6 haloalkyl, —(C1-6 alkylene)n-NH2, —(C1-6 alkylene)n-NH (C1-6 alkyl), —(C1-6 alkylene)n-N(C1-6 alkyl)2, or —(C1-6 alkylene)n-OH;
R2 is C1-6 alkyl;
R3, R4, and R7 are each independently chosen from: hydrogen, halogen, C1-6 alkyl, or —O (C1-6 alkyl);
R9 is hydrogen, C1-6 alkyl, C1-6 haloalkyl, or C3-8 cycloalkyl;
n is 0 or 1.